Your shopping cart is currently empty

ML334 (LH601A) is a transmembrane and potent NRF2 activator that inhibits Keap1-NRF2 protein interactions to ameliorate myocardial infarction-induced cardiac fibrosis by inhibiting cardiac fibroblast activation and proliferation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $49 | - | In Stock |
| Description | ML334 (LH601A) is a transmembrane and potent NRF2 activator that inhibits Keap1-NRF2 protein interactions to ameliorate myocardial infarction-induced cardiac fibrosis by inhibiting cardiac fibroblast activation and proliferation. |
| Targets&IC50 | Keap1:1 μM (Ki) |
| In vitro | Treatment of HEK293 cells with ML334 (LH601A; 50-100 μM; 6-16 hours) increases NQO1 and TRX1 mRNA levels by 2 to 3 times at both 6 and 16 hours. Additionally, at 6 hours, ML334 enhances HO-1 mRNA expression by 4 to 7 times, with a relatively smaller change in fold increase observed at 16 hours [2]. ML334 (LH601A; 50-100 μM; 16 hours; HEK293 cells) induces the expression of HO-1 and TRX1 proteins in HEK293 cells [2]. Furthermore, ML334 (LH601A) stimulates the expression and nuclear translocation of NRF2 in HEK293 cells [2]. |
| Synonyms | LH601A |
| Molecular Weight | 446.49 |
| Formula | C26H26N2O5 |
| Cas No. | 1432500-66-7 |
| Smiles | OC(=O)[C@H]1CCCC[C@H]1C(=O)N1CCc2ccccc2[C@H]1CN1C(=O)c2ccccc2C1=O |
| Relative Density. | 1.354 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (67.19 mM), Sonication is recommended. Ethanol: 30 mg/mL (67.19 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (11.2 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO/Ethanol
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.